4.5 Article

LINC01116 promotes proliferation and migration of endometrial stromal cells by targeting FOXP1 via sponging miR-9-5p in endometriosis

期刊

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 25, 期 4, 页码 2000-2012

出版社

WILEY
DOI: 10.1111/jcmm.16039

关键词

ceRNA; endometriosis; FOXP1; LINC01116; miR‐ 9‐ 5p

资金

  1. National Natural Science Foundation of China [81872125]
  2. Local Technology and Development Key Program of Liaoning Province [2019416020]
  3. Key Research and Development Guidance Plan of Liaoning Province [2018225062]

向作者/读者索取更多资源

The study reveals that LINC01116 promotes the progression of endometriosis through the miR-9-5p/FOXP1 axis, providing a novel therapeutic target for the disease.
Endometriosis is a common multi-factorial gynaecological disease. Recent studies have revealed that long non-coding RNAs (lncRNAs) are involved in the pathogenesis of endometriosis. In the present study, the expression profiles of lncRNAs in 6 pairs of endometriosis ectopic endometrium (ecEM) and eutopic endometrium (euEM) tissues were analysed by RNA sequencing. From the profiles, LINC01116 was found to be up-regulated in ecEM tissues compared to euEM tissues and was verified by quantitative real-time PCR (qRT-PCR). Then, functional experiments demonstrated that LINC01116 promoted the proliferation and migration of ectopic primary endometrial stromal cells (ESCs), while miR-9-5p exerted the opposite effects. Dual-luciferase reporter assays verified that LINC01116 directly sponged miR-9-5p and relieved the suppression of its target, Forkhead box protein P1 (FOXP1). Rescue experiments further demonstrated that LINC01116 could promote proliferation and migration of ESCs by targeting FOXP1 via sponging miR-9-5p. Overall, our study illuminates that LINC01116 promotes the progression of endometriosis through the miR-9-5p/FOXP1 axis. This finding provides a novel therapeutic target for patients with endometriosis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据